- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04429035
SLOW-Slower Progress of caLcificatiOn With Vitamin K2
Inhibition of Aortic Valve Calcification Through the Carboxylation Mechanism of Matrix Gla Protein (MGP), Following Administration of Vitamin K2 (Menaquinone-7). Correlation With Mitral Annulus and Ascending Aorta Calcification.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
For the purposes of this study, all individuals will be subjected to the same quantitative and qualitative tests, before and after the daily administration of 300mcg K2 vitamin/placebo for a period of one year.Clinical examination,extensive blood laboratory tests,direct measurement of Dephosphorylated-uncarboxylated MGP(dp-ucMGP), Echocardiogram and ECS,carotid ultrasound,ophthalmologic exam,further imaging methods with MSCT Calcium Score(Agatston score) will take place.Correlations with their medical and pharmacological therapy history.
Before and after the administration of VK2/placebo, the following measurements will take place i)Quantitative and percentile rate determination of Aortic Valve, Mitral Valve and Ascending Aorta calcification via MSCT Calcium score without contrast.
ii)Echocardiogram and calcification evaluation via Echocardiographic Calcium Score (ECS), iii)Determination of changes in carotid intima-media thickness (cIMT) and Carotid stenosis iv)Standard ophthalmologic examination v)Direct measurement of Dephosphorylated-uncarboxylated MGP(dp-ucMGP) vi)Correlation with blood biomarkers
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Symeon Evangelos Mavroudeas, MD
- Phone Number: 00306948694644
- Email: akis-m@hotmail.com
Study Contact Backup
- Name: Konstantinos P Toutouzas, Professor
Study Locations
-
-
Attiki
-
Athens, Attiki, Greece, 11527
- Recruiting
- First Department of Cardiology, University of Athens
-
Contact:
- Symeon Evangelos Mavroudeas, MD
- Phone Number: 00306948694644
- Email: akis-m@hotmail.com
-
Contact:
- Konstantinos P Toutouzas, Professor
- Phone Number: 00302132088147
- Email: ktoutouz@gmail.com
-
Athens, Attiki, Greece, 11527
- Recruiting
- Hippokration Hospital 1st Department of Cardiology,National and Kapodistrian University of Athens,Medical School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ASYMPTOMATIC AV STENOSIS WITH AVA>1 cm2 & Vmax<4m/s
Exclusion Criteria:
- AVK,STATINS,MSCT THE LAST 6 MONTHS,PROSTHETIC VALVES, AVA<1 cm2,Vmax>4m/s
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vitamin K2
Participants receive Vitamin K2 (Menaquinone) 100mcg tablet orally 3 times daily for 12 months.
|
Administration of 300 μg Vitamin K2 (MQ7) daily p.o
|
Placebo Comparator: Placebo
Participants receive Vitamin K2 (Menaquinone) placebo tablet matching Vitamin K2 (Menaquinone) orally 3 times daily for 12 months.
|
Administration of 300 μg Vitamin K2 (MQ7) Placebo daily p.o
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of calcification change of Aortic valve.Correlation With Mitral annulus and ascending Aorta calcification.A randomized 12-month trial.
Time Frame: Each patient will be evaluated twice a year.Once before the administartion of VK2/Placebo and after a period of a 12 month administration of VK2/PLACEBO
|
The calcification change will be evaluated via a 64 MSCT scanner measuring the calcium via Agatston score, before and after administration of VK2/placebo.The following measurements will take place and after 12 months will be compared.
|
Each patient will be evaluated twice a year.Once before the administartion of VK2/Placebo and after a period of a 12 month administration of VK2/PLACEBO
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Metabolic Diseases
- Pathological Conditions, Anatomical
- Aortic Valve Disease
- Heart Valve Diseases
- Ventricular Outflow Obstruction
- Calcium Metabolism Disorders
- Aortic Valve Stenosis
- Constriction, Pathologic
- Mitral Valve Stenosis
- Calcinosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Fibrin Modulating Agents
- Micronutrients
- Vitamins
- Antifibrinolytic Agents
- Hemostatics
- Coagulants
- Vitamin K
- Vitamin K 2
Other Study ID Numbers
- 55461
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Valve Stenosis
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
The Medicines CompanyCompletedTranscatheter Aortic Valve Replacement | Aortic Valve Replacement | Severe Aortic StenosisNetherlands, Germany, United Kingdom, Canada, France, Italy, Switzerland
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Edwards LifesciencesCompletedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Sorin Group USA, Inc.TerminatedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Hospices Civils de LyonRecruiting
-
Edwards LifesciencesCompletedAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Edwards LifesciencesActive, not recruitingHeart Failure | Aortic Stenosis | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Mitral StenosisUnited States, Canada, Poland
Clinical Trials on Vitamin K2
-
Université de SherbrookeSamuel Fortin, SFC pharma and associate professor UQARCompleted
-
Hopital St. Georges, AjaltounOmicron Pharmaceuticals; Nattopharma ASAUnknownAortic Valve DiseaseLebanon
-
Maastricht University Medical CenterVitaKCompleted
-
University of AarhusAxellusUnknownMetabolic Bone DisorderDenmark
-
Ain Shams UniversityUnknownEnd Stage Renal DiseaseEgypt
-
Ankara City Hospital BilkentRecruitingPerineal InjuryTurkey
-
Augusta UniversityYale University; University of Alabama at Birmingham; Tufts UniversityUnknownObesity | Diabetes | Insulin Resistance | Dyslipidemia | Insulin Sensitivity | PrediabetesUnited States
-
Chinese University of Hong KongRecruiting
-
Augusta UniversityUnknownHyperglycemia | Cardiovascular Diseases | Obesity | Insulin Resistance | Hyperlipidemia | Nutritional and Metabolic Diseases | Obesity in DiabetesUnited States